InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,193.77
(
0.25%
)
US TECH 100
17,670.40
(
0.34%
)
Dow Jones
38,920.60
(
0.18%
)
Brent Oil
82.86
(
-0.74%
)
Bitcoin
63,706.90
(
0.86%
)
Post# of 18784
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

~ Blue ~

Send PM Follow Ignore
Followers 2576
Posts 112748
Boards Moderated 1
Alias Born 08/25/2010

~ Blue ~

Re: None

Wednesday, 09/23/2015 11:58:20 PM

Wednesday, September 23, 2015 11:58:20 PM

Post# of 18784
AEZS cancer drug founder got Nobel Prize in Medicine

Zoptarelin doxorubicin was developed by Andrew V. Schally while at the Tulane University School of Medicine, New Orleans and subsequently at the Sylvester Comprehensive Cancer Center, University of Miami.

The U.S. Food and Drug Administration (FDA) has granted it orphan drug status for ovarian cancer and endometrial cancer.

https://en.wikipedia.org/wiki/Zoptarelin_doxorubicin


About Andrew Schally

Andrzej Viktor "Andrew" Schally (born November 30, 1926) is a Polish-American endocrinologist and Nobel Prize laureate (1977) in medicine, sharing the prize that year with Roger Guillemin and Rosalyn Sussman Yalow.


https://en.wikipedia.org/wiki/Andrew_Schally

AEZS~ August 25, NEW presentation!

http://www.aezsinc.com/pdfdyn/AEZS%20Presentation%20AUG_25-2015-FINAL.pdf

follow me on BLUE SKY BREAKOUT

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AEZS News
More AEZS News
InvestorsHub NewsWire

FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM

Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Start posting your company's news
Only $200 per official company press release!